Understanding and preventing heart damage from chemotherapy in African American children
Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
['FUNDING_R01'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10895517
This study is looking at how the chemotherapy drug doxorubicin affects the hearts of African American children with cancer, and it aims to find out if certain genes make them more likely to have heart problems, so we can make cancer treatments safer for them.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10895517 on ClinicalTrials.gov |
What this research studies
This research focuses on the effects of doxorubicin, a common chemotherapy drug, on the hearts of African American children who are treated for cancer. It aims to identify genetic factors that increase the risk of heart damage, known as cardiotoxicity, which affects a significant number of pediatric cancer patients. By using patient-specific stem cells, the researchers will explore how these genetic variants can predict the likelihood of developing heart issues. This innovative approach seeks to improve the safety and effectiveness of cancer treatments for young patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American children aged 0-11 years who are receiving treatment with doxorubicin for cancer.
Not a fit: Patients who are not African American or those who are not receiving doxorubicin as part of their cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prediction and prevention of heart damage in children undergoing chemotherapy, ultimately improving their long-term health outcomes.
How similar studies have performed: While there has been significant research on chemotherapy-induced cardiotoxicity, this specific approach using patient-specific stem cells in African American children is novel and has not been extensively tested.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BURRIDGE, PAUL W. — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: BURRIDGE, PAUL W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.